Your Elite Trading Review: Week of March 25

You are receiving this as part of your free subscription to Wall Steet Insights & Indictments. To remove your email from this list, unsubscribe here.

WITH SHAH GILANI Final Warning: This Could Be the Greatest Military Technology of the Century Our military could soon depend on this incredible class of devices - a technology so powerful it can actually hear an ant's footsteps. The Israeli army has gotten its hands on a few prototypes; the Minister of Defense already awarded it the first defense prize; and over 18 multibillion-dollar institutions have backed them as well. But tonight at midnight, your window of opportunity will slam shut. We have fewer than 200 spaces remaining to access this crucial briefing - and I can't guarantee you will see this again. This is your final notice... March 31, 2019 Dear Wall Street Insights & Indictments Reader, This week's going to be a busy one for me. As I told you yesterday, the Black Diamond Conference is happening Thursday to Saturday, April 4-6, in Delray Beach, FL this week. (Though attendance has maxed out, you can still watch us - and you'll definitely want to tune in Friday afternoon for mine. Click here to learn how to stream the conference live.) So, even though I'm so busy prepping for what I plan to be the best session I've ever given, I still wanted to write a quick note to you today on something dire - something that could actually change the world as we know it. It's considered by the European Journal of Physics to be "One of the greatest scientific achievements of all time." At the most basic level, it's a set of devices that may deploy any day now thanks to an executive order, and as soon as they do, they can save hundreds of thousands of lives, create 2.7 million jobs, and develop $3.9 TRILLION in wealth. What was once a small company that flew under the radar is now gaining recognition - and fast, even Bill Gates threw $60 million into the pot - so the company's value could go ballistic when these devices are released. But due to the time constraint, the offer to learn more about them is closing by midnight tonight. And by not clicking here to view the presentation on them, you could be kissing your chance at insurmountable gains goodbye. Don't be the one who missed out. Meanwhile, here's how our premium subscribers spent their week... We're Back in the Game After taking a week off to really consider all that the market is telling us, this week, we decided to take a little risk. Not a lot, because things are very rocky right now, but a little. The entity we've got our eye on this week, if all goes well, could see us holding stock worth possibly much more than it's worth now... [And you may be surprised at my reasoning behind this.] Hang in There What kind of trade recommendation can you put on in a market like the one we saw mid-week? How about an out-of-the-money straddle? We could buy out-of-the-money calls to profit if we breakout of the sideways drift and shoot for new highs. And, we could buy out of the money puts to profit if we breakdown and test the December lows. But, buying enough time, meaning going out 3-6 months, would be very expensive. And, the way things have been going, we could keep on keeping on going sideways... [But hang in there, for better days are coming.] The Untapped CBD Market Could Explode 400% The non-psychoactive cannabinoid known as CBD is having a moment. Thanks to the 2018 Farm Bill, the regulatory cloud in the U.S. over CBD is lifting, and that's great news for investors looking to tap yet another rich vein of potential profits in the marijuana gold rush. The Brightfield Group estimates the CBD market could climb to $22 billion in the next four years. But that's just the beginning. And Michael A. Robinson knows exactly what readers of Nova-X Report can do to make the most of this movement... [Full Story] How You Can Profit From This Medical Pioneer Most investors have never heard of the breakthrough drug championed by Michael A. Robinson's latest recommendation for readers of Radical Technology Profits. But for anyone who lives with the most painful forms of gout, it's a name that spells relief. Since this is an "orphan" disease, competition for the drug basically does not exist. That means profit margins are high, and doctors are prescribing the drug to a lot more of their patients, which means that the company that produces it could see a nifty share price hike... [And soon.] If you're already a member of these research services, make sure you haven't missed any of these crucial email alerts. If you're not yet a member, you can click on any of the links above to find out how you can get these exclusive trade recommendations delivered right to your inbox every week. You'll gain immediate access to our premium research, and you'll receive our exclusive trade recommendations as soon as we see a window of opportunity. Sharing the most profitable trading strategies with everyday readers is what we do best, and I don't want anyone to miss out. Here's to even more profit potential this week! I'll be back with you soon. Sincerely, Shah Share This Article: You are receiving this email at its028@gmail.com as a part of your free subscription to Wall Street Insights & Indictments. Remove your email from this list: Unsubscribe Manage Your Email Preferences To cancel by mail or for any other subscription issues, write us at: Wall Street Insights & Indictments | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 Contact Customer Service Website: https://wallstreetinsightsandindictments.com/ © 2019 Wall Street Insights & Indictments All Rights Reserved. Copyright - 2019 Money Map Press, LLC. The Money Map Press is a publishing company that does not act as a personal investment advisor for any specific individual. Nor do we advocate the purchase or sale of any security or investment for any specific individual. The proprietary recommendations and analysis we present to readers is for the exclusive use of subscribers. Readers should be aware that although our track record is highly rated, and has been legally reviewed for presentation in this invitation, investment markets have inherent risks and there can be no guarantee of future profits. Likewise, past performance is not necessarily indicative of future results. Stocks, futures, currencies, commodities, CFDs, options and all types of investment trading can have large potential rewards, but also carry large potential risks. We make absolutely no representation that gains or losses demonstrated in services published by Money Map Press LLC are likely or achievable. Please Note: Any performance results described herein are not based on actual trading of securities but are instead based on a hypothetical trading account which entered and exited the suggested positions in securities at the times and prices referenced. Hypothetical performance results have many inherent limitations. In fact, there are frequently sharp differences between hypothetical performance results and the actual results that may subsequently be achieved. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk in actual trading. For example, hypothetical trading examples cannot possibly take into account the impact of liquidity or buyer and seller demand, and do not allow for slippage and associated trading costs and concerns. One must be aware of the risks and be willing to accept them in order to invest in the markets. One should never trade with money that one cannot afford to lose, and one must accept that there will be losses, and one must be able to sustain these losses, both from a financial as well as an emotional perspective. Recommendations are for the exclusive use of subscribers and can change at any time. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Wall Street Insights & Indictments. 1125 N Charles Street, Baltimore MD 21201.